MP Group – Outlook of Protein Formulation Technologies – Opportunities for IV to subQ Conversion

Currently,~80% of biologics are administered intravenously due to high doses and challenges associated with high concentration protein formulation development – viscosity, stability including aggregation and volume. As a result, patients are tethered to IV infusion set-up for hours, few times a month often in a clinic or hospital, adding significant cost. Subcutaneous delivery enhances patient compliance and convenience, while significantly reducing the cost associated with hospitalization. Only a handful of technologies have attempted to address the protein formulation challenge, that…

Continue Reading
Close Menu